Please assess the completion status of the following clinical trial:

Trial Title: Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Serum total T below 300 ng/dL based on 2 consecutive blood samples obtained between 6 and 10 AM, on two separate days at approximately the same time of day, following an appropriate washout of current androgen replacement therapy.~2. Subjects should be diagnosed to be primary (congenital or acquired) or secondary hypogonadal (congenital or acquired).~3. Naïve to androgen replacement or has discontinued current treatment and completed adequate washout of prior androgen therapy. Washout must be completed prior to collection of baseline serum T samples to determine study eligibility.~Exclusion Criteria:~1. History of significant sensitivity or allergy to androgens, or product excipients.~2. Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up.~3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s).~4. Subjects with symptoms of moderate to severe benign prostatic hyperplasia.~5. Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis~6. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus antibodies (HIV Ab).~7. History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.~8. History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study drug administration.~9. History of stroke or myocardial infarction within the past 5 years.~10. History of or current or suspected prostate or breast cancer.~11. History of untreated and severe obstructive sleep apnea.~12. History of long QT syndrome (QTc \> 450) or unexplained sudden death in a first degree relative (parent, sibling, or child).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Oral testosterone undecanoate, LPCN 1021 (Type: EXPERIMENTAL): Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).